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Abstract
The IMV envelope protein D8 is an adhesion molecule and a major immunodominant antigen of vaccinia virus (VACV). Here
we identified the optimal D8 ligand to be chondroitin sulfate E (CS-E). CS-E is characterized by a disaccharide moiety with
two sulfated hydroxyl groups at positions 49 and 69 of GalNAc. To study the role of antibodies in preventing D8 adhesion to
CS-E, we have used a panel of murine monoclonal antibodies, and tested their ability to compete with CS-E for D8 binding.
Among four antibody specificity groups, MAbs of one group (group IV) fully abrogated CS-E binding, while MAbs of a
second group (group III) displayed widely varying levels of CS-E blocking. Using EM, we identified the binding site for each
antibody specificity group on D8. Recombinant D8 forms a hexameric arrangement, mediated by self-association of a small
C-terminal domain of D8. We propose a model in which D8 oligomerization on the IMV would allow VACV to adhere to
heterogeneous population of CS, including CS-C and potentially CS-A, while overall increasing binding efficiency to CS-E.
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Introduction
Vaccinia virus (VACV) is a low virulence orthopoxvirus that
was used to eradicate smallpox [1]. Immunization with VACV
leads to the production of potent protective antibodies that target
the VACV envelope proteins A27, A33, B5, D8, H3 and L1,
among others [1]. VACV has two forms of infectious virions. The
intracellular mature virion (IMV) is the most abundant form of
VACV and mainly responsible for viral spread between hosts.
A27, D8, H3 and L1 are expressed on the outer membrane of
IMV. A33 and B5 are embedded in the more fragile extracellular
enveloped virion (EEV), which has an additional host cell derived
envelope. EEV is thought to be involved in cell-to-cell spread
within the host and is critical for virulence. Antibody responses
against VACV potently target both infectious forms of the virus,
likely contributing to the efficacy of the smallpox vaccine [2].
Among the VACV envelope proteins, A27, H3 and D8 are viral
adhesion molecules that bind to glycosaminoglycans (GAG) for
attachment to host cells. GAGs are linear polysaccharides with
repeating disaccharide units predominantly found on cell surfaces
and as constituents of the extracellular matrix [3]. While A27 and
H3 interact with heparan sulfate (HS) or heparin (HP) [4,5], D8
binds to chondroitin sulfate (CS) [6]. Viral adhesion to GAGs
represents a major route of entry for a range of pathogens [7]. As a
result, GAG adhesion is an early and important step that initiates
viral infection.
We have recently determined the crystal structure of the CS
adhesion protein D8 [8]. The N-terminal ectodomain contains a
carbonic anhydrase fold (CAH, residues 1–234), followed by a
smaller domain of unknown function (residues 235–273). A single
transmembrane domain (TM, 274–294) and a small intra-virion
tail (295–304) constitute the rest of the protein. The CAH domain
was suggested to be responsible for CS binding, as it has a central
positively charged crevice that complements the negative charge of
CS [8].
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We have recently identified four different antibody specificity
groups among an ensemble of twelve murine monoclonal
antibodies specific to D8 [9]. D8 MAbs were first sorted by
competitive ELISA according to their targeted epitopes on the
basis of which other MAbs they cross-block. Four main specificity
groups resulted from this experiment (group I: JE11; II: AB12 and
CC7.1; III: BG9.1, BH7.2, EB2.1, EE11, JA11.2, JE10, and JF11;
IV: FH4.1 and LA5) [9]. Partial epitope definitions for each of the
antibody groups were previously determined. For group I MAbs,
the epitope definition was mapped by Deuterium Exchange Mass
Spectrometry (DXMS) to residues 10–14 and 80–90 [9]. Peptide
ELISA, using 20-mer peptides that overlap by 10 amino acids and
cover the entire D8 protein sequence, suggested that group II
antibodies target a linear epitope called peptide 58 (residues 91–
110), while groups I, III and IV target a conformational epitope
[9]. Alanine scanning of peptide 58, and D8 point mutation
analysis (PMA) refined the group II epitope to 10 residues (H95,
W96, N97, K99, Y101, S102, S103, E106, H110 and D112).
While the group III MAb epitope is conformational, group III
MAbs can also bind peptide 58, albeit much weaker than group II
antibodies. Interestingly, group II and III MAbs cross-block each
other. Alanine scanning of peptide 58 gave a partial definition of
the group III epitope; it includes, but is not limited to H95, W96,
N97, Y101, S103, Y104, E105, E106, and K108. Finally, X-ray
crystallography identified the D8 epitope of one MAb of group IV,
LA5 [8].
In this study, we used glycosaminoglycan microarrays printed
with natural polysaccharides enriched in specific sulfated struc-
tures to identify the molecular species of CS that optimally binds to
D8 [10,11]. We further asked whether any of the antibodies that
target different binding sites on D8 block D8 adhesion to CS.
Lastly, using single particle electron microscopy (EM), we mapped
the binding site of a representative antibody of each antibody
specificity group on D8. Identification of different binding sites on
D8 illuminates the molecular details of the murine antibody
response against viral D8. Finally, we discovered two opposing
sides of the D8 protein surface that are not targeted by antibodies,
likely due to their inaccessibility in the viral membrane, and we
propose a model in which D8 forms a hexamer. The hexameriza-
tion is mediated by self-association of the previously uncharacter-
ized C-terminal ectodomain (residues 235–273) downstream of the
CAH domain.
Results
Identification of CS-E as an optimal ligand for D8 and role
of MAbs in blocking CS-E adhesion
To broadly assess D8-GAG interactions, we employed micro-
arrays containing immobilized chondroitin sulfate polysaccharides
enriched in specific sulfation motifs (CS-A, -C, -D, and –E),
dermatan sulfate (DS), hyaluronic acid (HA), heparin and heparan
sulfate (HS). We observed weak binding of monomeric D8 to
chondroitin sulfate, a CS preparation containing a mix of sulfation
motifs (CS-A, -C, -D, and –E). In contrast, D8 displayed strong
concentration-dependent binding to CS-E. Binding to heparan
sulfate or chondroitin sulfate with different sulfation patterns was
not observed (Fig. 1A).
Having identified the optimal ligand for D8, we then
determined the role of anti-D8 antibodies in preventing D8
binding to CS-E using a competition-binding assay. A represen-
tative of each of the four antibody specificity groups was first pre-
incubated at a saturating concentration with D8 and then tested
for binding to CS-E on the GAG microarrays. If the antibody
bound at the CS-E binding site on D8, no (or greatly reduced)
binding of CS-E would be observed. In contrast, full binding to
CS-E would occur for antibodies bound at a site separate from the
CS-E binding site. The extent of the CS-E blocking ability (%) of
the MAb indicated the degree of overlap of the two binding sites
(MAb epitope and CS-E binding site). Cross-blocking power may
be explained in terms of intersecting buried surface areas (BSAs),
or in terms of competing intermolecular electrostatic interactions.
Group I and II MAb representatives JE11 and CC7.1 did not
affect D8 binding to CS-E significantly, indicating that their
epitopes do not overlap with the CS-E binding site on D8 (Fig. 1B,
D). LA5, a member of group IV, fully abrogates CS-E binding to
D8, as we had previously suggested [8] (Fig. 1B, D).
Group II and III MAbs were previously identified to bind
peptide 58 (residue 91–110). Residues 91–110 are located on one
side of the positively charged crevice of D8 that we previously
proposed to be the CS binding site, using computational docking
[8]. While group II antibodies did not interfere with CS-E binding,
group III antibodies BH7 and EE11 blocked CS-E binding to
varying degrees. These results illustrated diversity in this group,
which constitutes the majority of the anti-D8 antibodies (eight out
of twelve). Despite both group II and III antibodies binding to
peptide 58, they surprisingly have different effects on CS-E
binding, indicating that they have an overlapping epitope but
differ in their binding footprint at the CS-E binding site on D8.
Because group II and III MAbs target overlapping epitopes
juxtaposing the sugar-binding site, we found such a wide variation
in CS-E blocking (BH7 40%, EE11 80%) quite surprising within a
single specificity group. As EE11 and BH7 are the most distant
representatives of group III antibodies, based on their light chain
(LC) sequences (Fig. S1), we next asked whether the other group
III antibodies have intermediate CS-E blocking abilities. We tested
6 out of all 8 Group III MAbs. We also used monomeric D8,
instead of the oligomer, to avoid potential steric hindrance of
antibody binding to D8, which itself could result in CS-E blocking
differences (Fig. 1C). Nevertheless, BH7 and EE11 blocked
binding to monomeric D8 similarly when compared to oligomeric
D8 (30 vs. 40% for BH7 and 60 vs. 80% for EE11). All other
analyzed Group III MAbs fall within the same CS-E blocking
range (35–60%), indicating subtle differences in their binding
footprint at the CS-E binding site of D8 (Fig. 1C, D). Since group
II MAbs did not cross-block CS-E, in contrast to group III MAbs,
we proposed that the shared epitope residues of peptide 58 could
not be responsible for the group III MAbs cross-blocking of CS-E
Author Summary
Vaccinia virus (VACV) is an orthopox virus and considered
the gold standard of vaccines as it was used to eradicate
smallpox from the human population. Inoculation with
VACV leads to a strong B cell immune response and the
production of potent antibodies that simultaneously
target several envelope proteins of the virus. Among
those viral proteins, D8 is an adhesion molecule that binds
chondroitin sulfate, a glycosaminoglycan, on the host cell
surface. Here, we identified chondroitin sulfate E (CS-E), as
the preferred ligand for D8 and assessed the role of a panel
of anti-D8 antibodies in preventing D8 binding to CS-E. We
further mapped the binding site of each antibody on the
D8 surface to reveal the targeted epitopes. Finally, using
several truncated D8 constructs, we identified that the C-
terminal domain of D8 that is not involved in CS-E binding
is in fact involved in oligomerization of native D8 in vitro
and likely, also on the virion, as a means of increasing
binding affinity to increase viral adhesion to CS on the host
cell.
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(amino acids H95, W96, N97, Y101, S103 and E106) [9]. K108,
however, is unique to the group III epitope and is involved in CS-
E binding, based on our docking result (see below). Therefore, we
hypothesized that residue K108 is responsible for cross-blocking
differences between group II and group III. Other intersecting D8
residues are necessarily involved in the case of group III MAbs that
induce high levels of CS-E blocking, such as EE11 (60–80% cross-
blocking; Fig. 1B, C).
These CS-E binding data led us to refine our previous docking
results by using a dodecasaccharide fragment of CS-E, instead of
the previously used CS-A [8]. In the docked model, each sulfate
group is found in the vicinity of the charged D8 residue pairs
K48/K98, R44/K108, and K41/R220, delineating the crevice,
which corroborates the high specificity of CS-E over CS-A that
was used for docking prior to our knowledge of the exact ligand
(Fig. 2A). In effect, CS-A bears only one sulfate group, on 49-
hydroxyl of GalNAc, while CS-E has an additional sulfate on the
69-hydroxyl group. Hence, docking data converged with the
experimental definition of the ligand, since it pointed to the
aforementioned positively charged residual pairs that are probably
Figure 1. D8 binds to CS-E and anti-D8 MAbs display different levels of competition with CS-E. A. GAG microarray performed with
monomeric D8 antigen. B. MAb/CS-E cross-blocking experiments using representatives of all four antibody specificity groups and oligomeric D8. C.
MAb/CS-E cross-blocking of group III MAbs D. Summary of CS-E cross-blocking abilities of various MAbs. Group III MAbs are characterized by large
variations in cross-blocking ability. Microarray binding experiments were performed in triplicate, and the data represent the average of 10 spots per
concentration averaged from the three experiments (6SEM, error bars).
doi:10.1371/journal.ppat.1004495.g001
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necessary to form salt bridges with both sulfate moieties. Alanine
substitutions of residues lining the crevice led to moderate (R220A)
or severe (R220A/R44A, and R220A/K48A) reductions in CS-E
binding (Fig. 2B). This suggests that D8 binding to CS-E is likely
mediated by a network of electrostatic interactions that form pairs
on opposing sides of the entire D8 crevice, involving residues K41,
R44, K48, K98 and K108 (Fig. 2A). In the D8/LA5-Fab complex
[MAb of group IV, pdb code 4ETQ], we observed that only two
of these residue pairs (K41/R220 and R44/K108) are part of the
epitope. However, LA5 fully blocks CS-E binding of D8, even
without K48/K98 coverage.
Identification of anti-D8 MAb epitopes by EM
Determining the full epitope for group II and III MAbs is
necessary to explain the wide spread in CS-E blocking ability (10–
80%) observed between group II and group III MAbs. To address
this question, we used negative stain single particle D8:Fab EM
reconstructions. To map the relative positions of the different
antibodies on D8, we used Fabs from two different groups,
simultaneously bound to D8. JE11-Fab (group I) was included as a
reference in all subsequent ternary complexes because it does not
cross-block binding of any other MAb groups [9]. We then
reconstructed the three-dimensional arrangements by embedding
individual atomic models within the low-resolution maps of the
multivalent complexes obtained by EM. Docking was guided using
previously determined experimental constraints: X-ray crystallog-
raphy definition of group IV epitope, DXMS definition of group I
epitope, and alanine-scan definitions of groups II and III epitopes
[9]. Since we had previously determined the high-resolution
crystal structure of D8/LA5 (group IV), we first reconstructed the
D8/JE11/LA5 complex (Fig. 3). We then reconstructed the D8/
JE11/CC7.1 complex, since a definition of the group II epitope
was available (Fig. 4). Fitting of those reconstructed atomic models
gave best-fit correlation values of 0.9016 and 0.9207, respectively.
These two first processes served as an internal proof of concept,
illustrating that our experimental epitope definitions agreed with
the associated EM maps.
Total BSA for group I (JE11) D8:MAb interface is 1238 A˚2. EM
data suggests the following additional residues for group I epitope,
adding to the strict definition previously obtained by DXMS: N9,
D75, Y76, Q122, L124, D126, K163, T187, P188, and N190
(Fig. 3B, C). Looking back at the DXMS data [9], we saw that
most of the aforementioned residues are in D8 regions where
deuterium (H2) exchange decreased upon complex formation, but
was weak or inconsistent. Most of these additional residues interact
with the JE11 light chain (Fig. 3B, C).
The group II (CC7.1) MAb:D8 interface has a total BSA of only
851 A˚2, which correlates with the linear nature of group II
epitope. Residues 91–110 correspond to a protruding region at the
surface of D8. Only minor differences were observed for the group
II epitope when comparing EM data to group II alanine scanning
definition: EM defined additional residues K98 and K100 as part
of the epitope (Fig. 4). However, K98A and K100A showed no
reduced binding to MAb CC7.1 [9], suggesting that both residues
do not contribute greatly to antibody binding.
Group III (EE11) epitope definition by EM
We used EE11-Fab to build a group III ternary complex for
which we did not have a full definition (Fig. 5). Model-to-map
correlation for this complex was 0.9115. The total EE11:D8 BSA
was 1710 A˚2, which is larger than group I and II epitopes but
smaller than group IV (2434 A˚2). A total of twenty-six D8 residues
interact with EE11 MAb. Six D8 residues interact with the light
chain (LC) and twenty-four with the heavy chain (HC) (Fig. 5B,
C). Novel D8 contacts are E30, T34, T35, R44, N46, F47, K48,
G49, G50, Y51, N59, E60, V62, L63, S64 and additional peptide
58 residues K98, K99, K100 and S102, with residues involved in
CS-E binding indicated in bold. Group IV (LA5) footprint (in
orange) intersects with the group III (EE11) epitope at residues
R44 and K108 (Fig. 5C).
Figure 2. Mapping of the CS-E binding site on vaccinia D8 ectodomain. A. Docking of CS-E dodecasaccharide to D8. Framed regions
highlight regularly spaced, positively charged residue pairs K41/R220, R44/K108, and K48/K98, which are predicted to interact with negatively
charged sulfate moieties of CS-E. B. Mapping of CS-E binding site. Mutation R220A led to a,50% decrease in CS-E binding compared to wt, while CS-
E binding to the double mutants R220/R44 and R220/K48 was almost fully abrogated, corroborating the CS-E docking model. Data were averaged
from three experiments.
doi:10.1371/journal.ppat.1004495.g002
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Figure 3. Group I (JE11) footprint. A. EM reconstruction of the D8 monomer in complex with Fab’s JE11 (group I) and LA5 (group IV) at 24 A˚
resolution. Projection Matching and Fourier Shell Correlation (FSC) are shown in figure S5. Top left inset shows one of the class-averages used for
building the map. EM density is shown in gray mesh. D8 monomer crystal structure is represented as a grey surface except for epitope footprints that
follow the same color code as [9]: group I (JE11): red; group IV (LA5): orange. Actual Fab chains also follow this color code. B. Summary of JE11 (group
I) contacts. D8 residues in red belong to the initial definition of group I epitope, assessed by DXMS. Salmon-colored residues complete the definition
of group I conformational epitope. Black bold-contours highlight residues previously picked for mutation analysis [9]. C. Footprint of completed JE11
epitope. Red and salmon footprints evidence initial and additional epitope residues. Despite being juxtaposed to each other, group IV (LA5) and
group I (JE11) footprints do not intersect. Black labels inform on residues resulting in a loss of MAb/Ag affinity upon mutation to alanine, while
mutated residues in white did not lead to any relevant change in binding.
doi:10.1371/journal.ppat.1004495.g003
Figure 4. Group II (CC7.1) footprint. A. EM reconstruction of the D8 monomer in complex with Fabs JE11 (group I) and CC7.1 (group II) at 21 A˚
resolution. See figure legend 3 for general description. Projection Matching and Fourier Shell Correlation (FSC) are shown in figure S6. Epitope
footprints follow the same color code as [9]: group I (JE11): red; group II (CC7.1): green. B. Summary of CC7.1 (group II) contacts. D8 residues colored
in forest green belong to the initial definition of group I epitope, assessed by alanine scanning. Lighter green residues complete the definition of
group II epitope. C. Footprint of completed CC7.1 epitope. Forest green and light green footprints evidence initial and current epitope definitions.
Group IV (LA5) footprint in orange does not intersect with group II (CC7.1) epitope.
doi:10.1371/journal.ppat.1004495.g004
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The resolution of the EM maps obtained with negative staining
provides an accurate epitope definition of group III but not at
atomic resolution. In order to validate this newly defined interface,
we picked three seemingly critical residues for alanine scanning
mutagenesis, two of which are involved in CS-E binding (E30,
R44, K48). A 3-fold decrease in affinity was observed for D8
E30A (Fig. S2). However, this was likely due to suboptimal folding
of D8 E30A, as the control antibody (JE11) also showed reduced
binding (9-fold). In both cases, only the association phase was
affected. This suggested that E30 does not contribute greatly to
EE11 binding. We observed an almost 10-fold decrease in EE11
affinity with D8 R220A/R44A and R220A/K48A mutants
compared to either wild-type (wt) D8 or R220A D8, suggesting
both R44 and K48 are important residues for EE11 binding (Fig.
S2). Both mutants bound normally to control antibodies. Figure 6
summarizes the details of and the techniques used to identify the
complete murine D8 epitome.
Most of the CS-E binding residues of D8 are targeted by the
HC of EE11 (K41, R44, K98, and K108), while the EE11 LC has
a single contact (K98; Fig. 5B). Hence, our model is compatible
with the general assumption that the HC frequently drives most
Ag/MAb interactions [12]. However, the EM model does not
corroborate our hypothesis that LC differences were responsible
for the CS-E blocking differences within group III.
D8 oligomerization is mediated through the C-terminal
domain
For structural studies, we prepared monomeric D8 that either
only contains the CAH domain (residues 1–234) or lacks the distal
C-terminal cysteine (C262, residues 1–261). However, we have
previously shown that the full D8 ectodomain forms a disulfide-
linked dimer (through C262) that further associates non-covalently
to form an oligomer [8]. Despite oligomeric D8 having an
molecular weight that was considerably larger than the 158 kDa
MW marker on SEC, we had previously described the D8
oligomeric state as tetrameric, based on D8 migration during
native gel electrophoresis [8]. However, size exclusion chroma-
tography with inline multi-angle light scattering (SEC-MALS),
assigned an average MW of 228 kDa for the D8 oligomer
compared to 42 kDa obtained for the D8 monomer, using two
different SEC resins (Fig. S3). The SEC-MALS data indicate a
hexameric D8 arrangement. EM class averages of the D8 oligomer
revealed no more than 7 drupelets, with 6 drupelets surrounding a
central drupelet that appears of lesser intensity (Figs. 7A, S3 and
S4). While a D8 heptamer remained a possibility, our SEC data
coupled to non-reducing SDS-PAGE suggested that the D8
oligomer is formed by en even number of D8 monomers. When
subjected to SEC both D8 oligomers, either lacking (1–261) or
containing (1–262) the C-terminal cysteine, eluted at the identical
volume (Fig. 7). When the D8 oligomers were subjected to non-
reducing SDS PAGE, no D8 monomer, but only disulfide-linked
D8 dimers were observed [8]. Therefore, only an even numbered
D8 oligomer, such as a hexamer appears possible, as an octamer
would not be supported by the SEC-MALS data. We speculate
that the 7th and central drupelet is not a result of heptameric D8
but rather formed by the convergence of the C-terminal
extremities (235–262) of all six D8 subunits (SUs). We confirmed
the monodispersity of the sample by size SEC-MALS (Fig. S3),
Figure 5. Group III (EE11) footprint. A. EM reconstruction of the D8 monomer in complex with Fabs JE11 (group I) and EE11 (group III) at 22 A˚
resolution. See figure legend 3 for general description. Projection Matching and Fourier Shell Correlation (FSC) is shown in figure S7. Epitope
footprints follow the same color code as [9]: group I (JE11): red; group III (EE11): blue. Actual Fab chains follow the same color code. B. Summary of
EE11 (group III) contacts. D8 residues colored in blue belong to the initial definition of group III epitope, assessed by alanine scanning. Cyan residues
complete the definition of group III epitope. C. Footprint of completed EE11 epitope. The initial definition obtained by alanine scanning and PMA is
depicted in blue and the current definition deduced from the EM particle reconstruction is in cyan. Group IV (LA5) footprint in orange does intersect
with group III (EE11) epitope at residues R44 and K108 (orange/cyan or orange/blue stripes).
doi:10.1371/journal.ppat.1004495.g005
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Figure 6. Summary of D8 murine epitome and CS-E binding site. A. Updated footprint of groups I (red), II (green), III (blue) and IV (orange)
are represented. The yellow line reminds the CS-E path between positively charged residue pairs (black frames). B. Summary of D8 epitope residues
for all VACV anti-D8 murine MAbs of the four epitope groups. Resolution depends on the method used for a specific assessment. Newly-defined
epitope residues are highlighted in bold italic. Residues in red are important for both CS-E, and group III and IV MAb binding.
doi:10.1371/journal.ppat.1004495.g006
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which suggested that 2D class averages are of a single species, and
most likely represent different orientations of the hexamer (Fig.
S4A). However, obtaining three-dimensional maps of the D8
hexamer was problematic due to apparent conformational
flexibility of D8. In fact, the CAH fold domains do not adopt a
uniform arrangement in the different hexameric D8 class averages
of figure 7A, but are instead placed haphazardly around the
central drupelet, likely due to flexibility of the connecting linker to
the C-terminal domain. The C-terminal domain was also
disordered in the crystal structure of D8 [8]. Hence, multiple
conformations of the D8 hexamer prevent the reconstruction of a
three-dimensional model via EM. This flexibility also suggests that
CAH fold domains do not participate in the oligomeric interface
and correlates with an apparent higher MW for the D8 hexamer
(MW of 228 kDa compared to theoretical 192 kDa).
Until now, no function was assigned to the C-terminal domain
of D8. To test our hypothesis that this domain mediates
oligomerization, we compared SEC elution profiles of three D8
constructs of different lengths. D8 D262 is mostly monomeric
when cells are grown at 37uC, and has a surprisingly higher ratio
of hexamer when grown at lower temperature (30uC). This
construct was used to solve the structure of the D8 monomer/
LA5-Fab complex. In order to favor crystallization, we intention-
ally did not include unique cysteine 262. When including cysteine
262 (D8D263 construct), we observed a higher ratio of oligomer vs.
monomer (Fig. 7B). The third construct, D8D235, contains only
the CAH fold domain. D8D235 was solely monomeric, which
confirmed the mapping of the D8 oligomeric interface to the C-
terminal region. These findings now assign a function to this
domain. A model of the D8 hexameric arrangement is shown in
figure 7C. In this model, both sides of a D8 monomer are in close
proximity to the two neighboring D8 monomers. Those are also
the D8 surfaces that are not targeted by any of the murine
antibodies, likely due to inaccessibility, further validating the
hexameric ‘‘ring-like’’ model.
Finally we have assessed the role of D8 oligomerization in CS
binding, using the GAG microarray binding assay (Fig. 7D). A
40% increase in CS-E binding to oligomeric D8 compared to the
monomer was observed, correcting for the six times molar excess
of D8 monomer. Therefore, oligomerization increases binding
avidity. In addition, and maybe more importantly, slight binding
to other CS species could also be detected. This was especially true
for CS-C, and was also observed for CS-A to a low degree.
Together, with more optimal CS binding to host cells, we
speculate that D8 oligomerization increases viral avidity to CS-E
but also to other CS species. This may improve viral adhesion to
cells expressing low levels of surface CS-E, or heterogeneous
populations of CS.
Figure 7. D8 oligomeric interface is secluded to the C-terminal region 235–262. A. From top to bottom: selected class averages of (i)
unliganded D8 oligomer, (ii) oligomeric D8+JE11-Fab, and (iii) oligomeric D8+JE11-Fab+LA5-Fab. Despite the monodispersity of unliganded D8
oligomeric sample, particles showed a varying number of drupelets, because of their orientation on the EM grid. The class averages with the highest
number of drupelets always show six drupelets surrounding a central one (red arrows). B. SEC profiles of recombinant D8 D235, D262, and D263
suggest that D8 oligomerises through the C-terminal domain. SEC markers as grey curve with MW given in kDa. C. Putative D8 hexameric model
based on EM data and SEC-MALS using biochemical constraints relative to the dimer and oligomer interfaces. The black circle highlights the putative
seventh and central drupelet, arising from all six SU C-terminal extremities, converging toward the IMV envelope. D. CS-E microarray indicating that
D8 hexamer (0.33 mM) binds more effectively to CS-E compared to 6-times molar excess of D8 monomer (2 mM) E. GAG microarray obtained with D8
oligomer (0.1 mM). D8 oligomer binds CS-E with higher affinity than the monomer, and also weakly binds to other CS species but not to DS, HA,
heparin and HS. Micro array binding experiment was performed in triplicate, and the data represent the average of 10 spots per concentration
averaged from the three experiments (6SEM, error bars).
doi:10.1371/journal.ppat.1004495.g007
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Discussion
In this study, we have completed the determination of the
murine D8 antibody epitome, proposing a novel definition of the
group III epitope. Involvement of K108 explains the competition
between group III and IV MAbs. These data also explain why
group III MAbs block CS-E binding when group II does not.
Sequence analysis, together with the observed overlap of MAb
group II and III epitopes lead us to consider group II as a sub-
group of group III. The group II epitope is a linear, minimal
version of a larger epitope space that includes group III
conformational epitopes. Group III MAbs have increased CS-E
cross-blocking abilities as their epitopes diverge from linear to
conformational, as well as increase in size. As a result, CS-E cross-
blocking ability of these MAbs increased. Because EE11 includes
the maximal number of CS-E binding site residues that group III
MAbs may target (R44, K48, K98, K108), we believe that the
EE11 cross-blocking ability represents group III’s CS-E blocking
maximum. In contrast, glycan microarray data place BH7 at the
bottom end of group III MAb cross-blocking, and therefore the
BH7 epitope may (i) be narrower than EE11, and (ii) include at
least CS-E contacting residue K108. Group III MAbs display
cross-blocking levels between those of group II and IV. We
conclude that group III MAbs nuance their CS-E blocking abilities
by including additional CS-E binding residues to their epitope
(R44, K48, and/or K98). One can use CS-E binding data to
predict the size of their respective epitopes. CS-E blocking abilities
of all anti-D8 MAbs is hierarchized as follows: LA5.EE11$
JF11,JE10.BG9.JA11.BH7.CC7.JE11. Total BSAs of the
different groups’ epitopes can be ranked as follows: IV (LA5:
2434 A˚2) [8] .III (EE11: 1710 A˚2).I (JE11: 1238 A˚2).II (CC7:
851 A˚2). Consequently, we predict epitopes of group III JF11 and
JE10 to target a region similar to EE11 on D8’s surface that most
likely includes all four possible CS-E binding residues within this
epitope, since all three MAbs have maximal CS-E blocking
abilities within group III. JA11 is at the other end of the CS-E
blocking range, and therefore its epitope might be close to the
minimal definition for group III. Lastly, BG9 has an intermediate
blocking ability of 50%, suggesting it targets an intermediate-sized
epitope that includes K108 and no more than two other positively
charged residues, such as R44, K48, and/or K98.
The importance of D8/CS-E adhesion for subsequent VACV
infection remains unclear. It is conceivable that the CS-E ligand
may be restricted to small pools of target cells in certain organs
[13,14]. In vivo infection models have not been discriminative of
cells based on their surface sugar profiles. In addition, it is possible
that there are species differences in glycosylation between mouse
and man that alter poxvirus pathogenesis. Alternatively, the sugar
binding properties of D8, H3, and A27 may have evolved to be
redundant or combinatorial with each other. The highly sulfated
CS-E type has been shown to bind to heparin binding growth
factors midkine (MK), pleiotropin (PTN), heparin-binding epider-
mal growth factor-like growth factor (HB-EGF), FGF-16, and
FGF-18. As many of these growth factors are expressed in the
mammalian brain, it was proposed that CS-E and CS proteogly-
cans (CSPGs) are critical to the development of the brain and
central nervous system [15]. Subsequent work using an antibody
specific for the CS-E disaccharide revealed its presence in the
developing mouse brain. The associated strong expression of the
gene for GalNAc4S-6ST transferase confirmed that CS-E chains
are critical in brain development, with the implication that CS-E
chains participate in neurogenesis, axon guidance, and/or
neuronal survival [16].
Interestingly, a VACV D8 knockout was unable to infect the rat
brain, suggesting that D8 function is connected to neural tissues
[17]. An ex or in vivo experiment with cells displaying the CS-E+/
HP-/HS- phenotype is essential to test the hypothesis that
orthopoxviruses may use CS-E as a selective infection route. In
effect, an infectious route relying on a non-ubiquitous GAG such
as CS-E may be strategically effective, since the virus would avoid
binding to most cells and therefore more efficiently target the
desired cell types for infection. In addition, perhaps binding CS-E
is a strategy for orthopoxviruses to build dormant pools of virus, or
to travel long distances within axons of neural cells, for example.
However, such subtle mechanisms may be hidden under the main
infection routes that involve binding to heparin sulfate by the viral
attachment proteins A27 and H3 [4,5].
Materials and Methods
D8 cloning
D8 D262 construct (amino acids 1–261, lacking Cys 262) was
engineered and prepared as reported previously [8]. D8D263
(containing Cys 262) protein expression vector was designed by
modification of the pET-22b(+):: D8D262 expression vector
through site-directed insertion of the C262 mutation using the




The D8D235 construct contains only the carbonic anhydrase
domain of D8 and was obtained by overlapping PCR using the
following primers to amplify the D8D235 sequence from VACV
ACAM2000 genomic DNA with the Accuprime Pfx PCR Kit
(Invitrogen). Primer 1: 59-CTTTAAGAAGGAGATATACA-
TATG CAACAACTATCTCCTATT-39, Primer 2: 59-GT-
GGTGGTGCTCGAGAGAATAATATACTTCTGTGTCAT-
C-39 [18]. A 134:1 molar ratio of gel-purified PCR product to
pET22b(+) was mixed to 1 uL KOD HiFi Polymerase, 1 mL 106
KOD Buffer, 1 mL 8 mM dNTPs, 1 mL 10 mM MgCl2 in a final
10 mL reaction volume (Toyobo). The following thermocycler
protocol was then used: 98uC for 2 min, 20 cycles of 98uC for 30 s,
55uC for 30 s and 72uC for 8 min, followed by final extension at
72uC for 20 min. Template DNA was digested with DpnI for 1 hr
at 37uC and used to transform DH5a cells for plating on LB Agar
with ampicillin. DNA was isolated from 5 mL cultures of single
DH5a colonies by Miniprep (Fermentas) and successful cloning
was confirmed by sequencing (Retrogen).
For mapping of the CS-E binding site, D8 D262 R220A, R44/
R220, and K48/R220 were expressed and purified as reported
previously [9] with addition of a final size exclusion chromatog-
raphy (SEC) step to isolate monomeric fractions.
Protein expression and purification
BL21-CodonPlus(DE3)-RIL competent cells (Agilent) were
transformed with one of the D8 expression vectors and grown in
LB media with 1 mM Ampicillin at 37uC until OD600 ,0.6.
Protein expression was then induced with 1 mM IPTG for 4 hrs at
37uC, while shaking at 230 rpm. Cells were pelleted and
resuspended in lysis buffer containing 100 mM Tris pH 8.0,
300 mM NaCl, 0.5 mM EDTA, 20 mM Imidazole, 0.2 mM
PMSF and lysed under 20000 psi pressure using a microfluidizer
(Microfluidics). Cell lysate was clarified at 50,000 g for 20 min.
Supernatant was loaded onto 5 mL Ni-NTA column (His-Trap,
GE). Bound D8 protein was eluted with 20 mM Tris pH 8.0,
300 mM NaCl, 200 mM Imidazole. After overnight dialysis
against 20 mM Tris pH 8.0, 200 mM NaCl, the sample was
Natural Antibody Responses Interfere with D8/CS-E Adhesion
PLOS Pathogens | www.plospathogens.org 9 December 2014 | Volume 10 | Issue 12 | e1004495
concentrated and subjected to SEC using a Superdex 200 10/
300GL column (GE) in the same buffer. The monomeric peak
with VE>16.5 mL and oligomeric peak with VE>11.7 mL were
collected in separate fractions.
Glycosaminoglycan microarray assay
Microarrays containing natural GAGs enriched in CS-A, CS-C,
CS-D, and CS-E (Seikagaku Corp., Tokyo, Japan), dermatan
sulfate (DS; Sigma-Aldrich, St. Louis, MO), hyaluronic acid (HA;
Sigma-Aldrich, St. Louis, MO), heparin (Hep; Neoparin, Alame-
da, CA), heparan sulfate (HS; Sigma-Aldrich, St. Louis, MO), or
chondroitin sulfate (CS; Sigma-Aldrich, St. Louis, MO) were
printed on poly-DL-lysine-coated glass surfaces as described
previously [19,20]. Arrays were blocked with 10% FBS in 16
PBS with gentle rocking at room temperature for 1 h, followed by
a brief rinse with 16PBS. For binding and mapping experiments,
monomeric D8, monomeric D8 mutants R220A, R44A/R220A,
K48A/R220A, and oligomeric D8 were diluted to 2 mM
(monomeric) and 0.33 mM (oligomeric) in 16 PBS containing
1% BSA; 100 ml was spotted on the microarrays and incubated at
room temperature for 3 h. For antibody blocking experiments,
0.1 mM oligomeric D8 was incubated with 1 mM MAb (group I:
JE11; II: CC7; III: BH7; BG9; EE11; JA11; JE10; IV: LA5) or
alone for 1 h at room temperature; 100 ml was spotted on the
microarrays and incubated at room temperature for 3 h.
Microarrays were rinsed briefly three times with 16 PBS and
incubated with 1:200 rabbit anti-6-His (Bethyl Laboratories,
Montgomery, TX) for 1 h with gentle rocking, rinsed briefly
three times with 16 PBS, followed by 1:5,000 Cy3-conjugated
goat anti-rabbit IgG antibody (Jackson ImmunoResearch, West
Grove, PA) for 1 h in the dark with gentle rocking. The
microarrays were then washed (3 times of 16 PBS and 2 times
of de-ionized water), dried under a stream of air, and scanned
at 532 nm using a GenePix 5000a scanner. Fluorescence
quantification was performed using GenePix 6.0 software
(Molecular Devices, Sunnyvale, CA). CS-E cross-blocking
abilities of the four specificity group MAb representatives,
and of group III MAbs were calculated for a CS-E concentra-
tion of 5 mM.
D8/CS-E docking
CS-E ligand was built by fusing two CS-A hexasaccharides
extracted from CS/cathepsin K complex structure [pdb code
3C9E] [21]. Additional sulfate groups were added to the ligand at
position 69 of N-acetyl-beta-D-galactosamine-4-sulfate, and ligand
geometry was regularized and energy-minimized with PRODRG
[22]. Docking was performed with Autodock Vina using a D8
pdbqt-formatted structure file [23] along with chondroitin 4,6-
sulfate (CS-E) dodecasaccharide as ligand. In the original D8
coordinate file [pdb code 4E9O] [8], K48 Nj interacts with water
334, and water 326 of adjacent symmetry mate, and is pointing
outward, suggesting it is not constrained in solution. In order to
allow optimal docking of CS-E, side chain of residue K48 was
moved away from K98 side chain (Coot, rotamer 5, 4% likelihood,
Chi1 =2177u). Grid box dimensions (x, y, z = 120, 48, 54) and
center (x, y, z = 18.169, 20.779, 210.045) were defined based on
our early routines [8] in order to accommodate the new, larger
ligand.
Fab preparation
IgG’s were subjected to papain digestion to produce Fabs.
Conditions for digestion were as follows: EE11-IgG2a was digested
with 2% w/w activated papain in 50 mM NaOAc pH 5.5 reaction
buffer at 37uC over 3 hrs; JE11 and LA5-IgG2a were digested
with 2% w/w activated papain in 50 mM NaOAc pH 5.5 reaction
buffer at 37uC over 4 hrs; CC7.1 (IgG1) was digested with 2%
w/w activated papain in 100 mM Tris pH 7.0 reaction buffer with
10 mM cysteine at 37uC over 2 hrs. Papain digestion was
terminated by addition of 20 mM iodoacetamide. EE11, JE11,
and LA5-Fab containing samples were then dialyzed overnight in
5 L PBS pH 8.0. Samples were then passed through 1 mL FF
Protein A column (GE) in PBS pH 8.0 binding buffer and Fab was
collected in the flow-through. Fab was further concentrated for
subsequent purification by SEC using a Superdex 200 10/300GL
column (GE). Purified monomeric Fab peaks (VE>16 mL) were
collected for complex preparation. The CC7.1 Fab containing
sample was buffer exchanged against 3 M NaCl, 1.5 M Glycine
pH 8.9 for Protein A affinity purification. Flow-through was
dialyzed overnight against 5 L 20 mM Tris pH 8.0, 200 mM
NaCl and subjected to SEC using a Superdex 200 16/60HR
column (GE). Fractions containing monomeric Fab were collected
for complex preparation (VE>86.4 mL).
Complex preparation
Monomeric D8 protein was used to prepare the D8 ternary and
quaternary complexes with two different specificity groups Fab
molecules (D8/JE11/LA5, D8/JE11/LA5/CC7.1, and D8/
JE11/EE11). The D8/LA5 crystal structure was used to position
LA5-Fab in the EM map, while subsequently JE11 was used as a
position marker for single particle EM reconstruction, since it does
not cross-block binding of any of the other specificity group MAbs.
The D8 D263 oligomeric protein was used to assess the
physiological D8 oligomerization state with or without Fab
decoration.
D8/JE11/LA5. D8D262 monomer+JE11-Fab complex was
prepared by mixing 20% molar excess of D8D262 monomer to
purified JE11-Fab at low concentration (,0.2 mg/mL). Sample
was then incubated on ice for 5 minutes, concentrated, and loaded
onto a Superdex 200 10/300 SEC (GE). The D8D262 monomer+
JE11-Fab complex (,82 kDa) was pooled and mixed with LA5-
Fab at equimolar ratio. The ternary complex sample was
concentrated and purified by SEC (Superdex 200 10/300) as a
,152 kDa protein complex.
D8/JE11/LA5/CC7.1. This complex was prepared as de-
scribed above for D8D262 monomer+LA5-Fab+JE11-Fab, with
the final addition of CC7.1-Fab at equimolar amounts for a final
SEC step, where fractions corresponding to D8D262 monomer+
LA5-Fab+JE11-Fab+CC7.1-Fab quaternary complex were ob-
tained upon SEC as a ,200 kDa complex. Only few class-
averages pertained to the quaternary complex, and, therefore, this
sample lead only to 3D-reconstruction of the ternary complex D8/
JE11/CC7.1.
D8/JE11/EE11. The first step for preparing this complex is
similar to the ones mentioned above: JE11-Fab was added to 20%
molar excess of D8D235 monomer initially, followed by the
addition of a 20% molar excess of EE11-Fab to the purified
secondary complex pool for final SEC (Superdex 200 10/300). All
complexes were freshly SEC-purified prior to EM analysis, and
existence of the complex was validated by observation of a proper
shift of elution volume upon complex formation, and SDS-PAGE
analysis (Fig. S8).
Electron microscopy
Various complexes were prepared with either monomeric D8,
monomeric D8 together with the Fabs from either JE11 and
CC7.1, or JE11 and EE11, or JE11 and LA5, or oligomeric D8
either unliganded, or in complex with LA5-Fab, or with both
JE11- and LA5-Fabs. Samples were analyzed by negative stain
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EM. A 3 mL aliquot containing ,0.05 mg/mL of complex was
applied for 15 s onto a carbon-coated 400 Cu mesh grid that had
been glow discharged at 20 mA for 30 s, then negatively stained
with uranyl formate for 30 s. Data were collected using a FEI
Tecnai F20 or T12 electron microscope operating at 120 keV,
with an electron dose of ,27 e2/A˚2 and a magnification of
52,0006 that resulted in a pixel size of 2.05 A˚ at the specimen
plane. Images were acquired with a Gatan US4000 CCD or Tietz
TemCam-F416 CMOS camera using a nominal defocus of
1000 nm and the Leginon package [24] at 10u tilt increments
and up to 50u. The tilts provided additional particle orientations to
improve the image reconstructions.
Data processing and image reconstruction
Particles were picked automatically using DoG Picker and put
into a particle stack using the Appion software package [25,26].
Initial, reference-free, two-dimensional (2D) class averages were
calculated using particles binned by two via the Xmipp Clustering
2D Alignment [27] and sorted into classes. Particles corresponding
to complexes were selected into a substack and binned by two
before another round of reference-free alignment was carried out
using the Xmipp Clustering and 2D alignment and IMAGIC
software systems [28]. To analyze the interactions of the Fabs
(LA5, JE11 and CC7) with D8 monomer, the reference free 2D
class averages were examined. An ab initio common lines model
was calculated from reference-free 2D class averages in EMAN2
[29]. Fab densities were visible after 10 iterations. This model was
then refined against raw particles for an additional 89 cycles.
EMAN [30] was used for all 3D reconstructions. The resolutions
of the final models were determined using a FSC cut-off of 0.5. For
the 3D reconstruction of D8 monomer with JE11 plus LA5, a
number of 5291 particles were used. For the 3D volume of D8
monomer in complex with JE11 and CC7, a number of 8044
particles were used.
Fab modeling
Full Fab sequences were reconstructed from our in-house Fv
sequenced data. V-, D-, and J-alleles were identified using V-quest
of the international immunogenetics system [31]. For example, V-
and J-genes IGKV4-57*01 and IGKJ5*01 for k chain and V-, D-,
and J-genes IGHV14-3*02, IGHJ3*01, and IGHD2-3*01 for c2a
chain were assigned for JE11. JE11, CC7.1, and EE11 Fv were
modeled using Web Antibody Modeling (WAM) based on the
AbM package [32]. Isotype-specific constant region sequences
were determined using IMGT database and respective
atomic coordinates were appended to the Fv domain after
segment fitting.
Model fitting into the EM densities
First, a guided docking approach was used to obtain putative
models of D8/JE11-Fv, D8/CC7-Fv and D8/EE11-Fv: experi-
mental epitope definitions were used as input for Z-DOCK
docking ([33]; DXMS for JE11, and alanine scan for CC7 and
EE11) while assigning CDR residues as potential contacts in the
Ag/MAb interface (Kabat definition) while blocking D8 residues
that are not part of the epitope. The first ternary complex to be
reconstructed was D8/JE11/LA5; D8/JE11/LA5 EM density was
segmented into 5 regions corresponding to every domain (C1, Fv1,
D8, Fv2, C2), using the UCSF Chimera ‘Segment map’ function
[34]. Coordinates of D8/LA5-Fv were extracted from D8/LA5-
Fab structure [pdb code 4ETQ] and fitted into the D8/JE11/LA5
EM density. Best-score fit was selected, after testing possible
orientations. Putative ternary complexes were obtained by
superimposing D8/JE11-Fv docking models onto the EM
map-fitted D8/LA5-Fv complex, using Coot least square fit
(LSQ) algorithm and setting D8 as the reference molecule [35].
The resulting ternary complex with the highest map fitting score
was selected as the final solution, and conserved domains of LA5
and JE11 were fitted at last in the two remaining segments of the
map, located the farthest away from the D8 molecule. In the two
consecutive ternary complexes (JE11/D8/CC7 and JE11/D8/
EE11), a similar routine was applied by fitting the D8/JE11-Fab
model deduced formerly first. For the last model (JE11/D8/
EE11), D8 residues outside of the known epitope definition were
not blocked. The novel definition of group III epitope was defined
by submitting JE11/D8/EE11 model to the Contact Map Analysis
server [36]. Buried surface areas (BSA) were calculated using PISA
[37].
Point mutation kinetics analysis by BioLayer
Interferometry (BLI)
BLI affinity measurements were determined using the Octet
Red 96 (Forte´Bio Inc., Menlo Park, CA). Anti-mouse Fc Capture
(AMC) biosensors were pre-soaked in 16 kinetics buffer contain-
ing PBS pH 7.4, 0.01% BSA, 0.002% Tween 20 for 1 hour.
Antibodies were immobilized by dipping the AMC biosensors in
the antibody solution containing 16 kinetics buffer to a
concentration of 3 ug/mL for 300 s. For the baseline step, the
tips were soaked in 16 kinetics buffer for 300 s. Association was
measured by dipping the biosensors in monomeric D8D262
diluted in 16 kinetics buffer to concentrations of 20 nM, 10 nM,
5 nM, 2.5 nM, 1.25 nM, 625 pM, 312.5 pM, and 156.2 pM for
900 s. Dissociation was measured in 16 kinetics buffer for 1200s.
All steps are processed at 30uC/1000 rpm. Identical assays were
performed for wild-type D8D262, and D8D262 R220A, D8D262
E30A, D8D262 R44A/R220A, and D8D262 K48A/R220A
mutants against antibodies BH7, EE11 and JE11. A negative
control antibody A2C7 that targets the VACV antigen A33 was
run in parallel to all assays for subtraction of background binding
signal. Data was analyzed with the ForteBio Data Analysis
Software 7.1 (Forte´Bio Inc., Menlo Park, CA). Y-axis alignment to
baseline step and interstep correction to dissociation step were
selected to align curves. Aligned and subtracted curves were
processed using Savitzky-Golay Filtering. Curve fittings were
derived from application of the 1:1 binding model with full global
fitting.
Size-Exclusion Chromatography Coupled with Multi-
angle Light Scattering (SEC-MALS)
The D8 D262 wt monomer and the D8 D262 oligomer were
loaded onto either a Superose 6 10/30 or Superdex S200 10/30
SEC column (GE Healthcare), which were coupled to an AKTA
Avant FPLC system (GE Healthcare) with the following calibrated
detection systems: (1) HP1 1050 Hewlett-Packard UV detector; (2)
MiniDawn Treos multiangle light scattering (MALS) detector
(Wyatt); (3) quasielastic light scattering (QELS) detector (Wyatt);
(4) Optilab T-reX refractive index (RI) detector (Wyatt). Analysis
of the light scattering data coupled to UV280 and refractive index
protein concentration measurements allowed determination of the
molar mass of the eluting proteins by using the protein conjugate
template in Astra 6 software.
Supporting Information
Figure S1 Phylogenic analysis of light and heavy Fv
sequences of murine anti-D8 MAbs. Multiple alignment files
of anti-D8 HC and LC CDR sequences were obtained with
ClustalW2 [38] and used in Seaview 4.2 to generate the
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dendrograms [39]. Specificity groups are overlapped onto the
dendrograms, using the same color-code as for our previous study
[8]. Alignment highlights hypervariable regions H1, H2, H3 and
L1, L2, L3 and residues are color coded (orange: GPST; red:
HKR; blue: FWY, green: ILMV). Phylogenic analysis of HC-Fv
sequences closely correlates with the specificity grouping
obtained by cross-blocking ELISA [9]. However, group III
LC CDR sequences overlap with those of group I, II and IV
MAbs.
(TIF)
Figure S2 Point mutation kinetics analysis by BioLayer
Interferometry. Real-time binding curves of BH7-, EE11- (both
group III), and JE11- (positive control) MAbs to wild-type D8D262
and D8D262 R220A (positive controls) and indicated mutants to
assess the validity of our complementary group III epitope
definition. Association (900 s) and Dissociation (1200 s) steps are
represented. Curves are colored according to their specific antigen
concentration (80, 40, 20, 10, 5, 2.5, 1.25 nM and 625, 312.5, and
156.2 pM). Association rate (kon), dissociation rate (koff), affinity
(KD) constant, and fit quality scores are deduced from each set of
curves and reported in the bottom table. BLI experiment was
performed once
(TIF)
Figure S3 SEC-MALS of D8 D262. Elution volume and molar
mass (MM) for D8 D262 oligomer (A) and monomer (B) obtained
using Superose 6. Elution volume and molar mass (MM) for D8
D262 oligomer (C) and monomer (D) obtained using Superdex
S200. The horizontal dark line under each peak corresponds to
the MM of the eluting sample as determined by SEC-UV/MALS.
E. Reported SEC-UV/MALS MMs.
(TIF)
Figure S4 Negative stain EM data of unliganded and
Fab-bound D8 hexamer. 2D class averages of (A) unliganded
D8 hexamer, (B) D8 hexamer bound to JE11-Fab, and (C) D8
hexamer bound to JE11- and LA5-Fabs.
(EPS)
Figure S5 Negative stain of D8 monomer in complex
with Fabs LA5 (group IV) and JE11 (group I). A. Projection
matching. B. Fourier Shell Correlation graph.
(EPS)
Figure S6 Negative stain of D8 monomer in complex
with Fabs CC7 (group II) and JE11 (group I). A. Projection
matching. B. Fourier Shell Correlation graph.
(EPS)
Figure S7 Negative stain of D8 monomer in complex
with Fabs EE11 (group III) and JE11 (group I). A.
Projection matching. B. Fourier Shell Correlation graph.
(EPS)
Figure S8 Preparation of monomeric and oligomeric
D8/Fab complexes. A, B, and C. D8-monomer complexes.
Associated class averages can be seen in figures S5, S6, and S7 D.
D8-hexamer complexes. Associated class averages of unliganded
and Fab-bound D8 hexamers can be seen in figure S4. All
complexes are prepared by performing recursive SEC runs,
starting by purifying the D8 monomer or D8 hexamer, and
performing subsequent SEC runs for each additional Fab added to
the complex being prepared. Curves are colored according to their
order in the sequential process (SEC #1: orange, SEC#2: green,
SEC #3: red, SEC#4: cyan). MWapp markers in kDa are shown
for reference (grey curve). Based on the cross-blocking data, we
also built the quaternary complex D8/JE11/CC4.1/LA5 (panel a,
SEC#4). Existence of this complex is evidenced by the class
average in figure S9.
(TIF)
Figure S9 Quaternary complex D8/JE11/CC7.1/LA5.
A. Superimposed maps of D8/JE11/CC7.1 and D8/JE11/EE11
ternary complexes, showing a ,90u rotation in the way group II
and III Fab molecules anchor onto the D8 antigen. B.
Reconstruction of D8/JE11/CC7.1/LA5 quaternary complex,
obtained by overlapping ternary complexes of figures 3 and 4.
(EPS)
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